Grifols, S.A.
NASDAQ:GRFSDrug Manufacturers - General
+$0.03 today
- Market cap
- $7.17B
- Beta
- 1.17
- P/E (TTM)
- 14.7
- EPS (TTM)
- $0.61
- Dividend yield
- 1.67%
Volume 0.59M
Average 0.69M
GRFS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Grifols, S.A.NASDAQ: GRFS
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization grows in line with its trailing trend
Q2 FY2026 depreciation & amortization of €107M rose 0.0% year over year, behind the +1.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +1.7% a year.
Context
- Depreciation & amortization amounted to 6.0% of revenue in FY2025, unchanged from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +1.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
EUR · from the cash flow
- Latest · FY2025
- 432.24M EUR
- Year-over-year change
- -1.3%
- 4-year CAGR
- +4.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 432.24M | -1.3% |
| FY2024 | 2024-12-31 | 437.9M | -1.9% |
| FY2023 | 2023-12-31 | 446.42M | +8.6% |
| FY2022 | 2022-12-31 | 410.98M | +14.2% |
| FY2021 | 2021-12-31 | 359.77M | — |
Depreciation & Amortization vs competitors
How GRFS compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.5% is the 2nd highest of 9, against a peer median of -3.7%.
- Depreciation & amortization amounts to 6.0% of revenue for GRFS, versus a peer median of 8.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.33B USD | +5.9% | -1.6% | 7.1% | |
| LTM Sep 2026 | $2.24B USD | -4.2% | -0.7% | 11.1% | |
| LTM Mar 2026 | $447.8M USD | +0.5% | +15.9% | 16.9% | |
| LTM Jun 2026 | €443.93M EUR | +1.5% | +1.7% | 6.0% | |
| LTM Jun 2026 | $127.6M USD | -23.5% | +6.4% | 4.9% | |
| LTM Jun 2026 | $110.07M USD | -4.5% | +6.2% | 8.1% | |
| LTM Sep 2026 | $96.75M USD | -8.8% | -3.2% | 7.9% | |
| LTM Jun 2026 | $56.96M USD | -3.2% | +16.6% | 27.3% | |
| LTM Jun 2026 | $7.69M USD | -2.8% | +4.4% | 1.5% | |
| Peer median (excluding GRFS) | — | -3.7% | +5.3% | 8.0% | |
Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 188.73M | 361.26M | 207.02M | 444M | 386.13M |
| Depreciation & Amortization | 359.77M | 410.98M | 446.42M | 437.9M | 432.24M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (181.36M) | (609.22M) | (362.84M) | 22.38M | (24.01M) |
| Accounts Receivables | (16.81M) | (80.17M) | (68.82M) | (41.88M) | (30.74M) |
| Inventory | (157.47M) | (600.25M) | (411.44M) | 25.82M | (93.17M) |
| Accounts Payables | 0 | 80.21M | 0 | 0 | 90.29M |
| Other Working Capital | (7.08M) | (9.01M) | 117.41M | 38.44M | 9.61M |
| Other Non-Cash Items | 229.84M | (173.89M) | (71.91M) | (2.1M) | 211.32M |
| Operating Cash Flow | 596.98M | (10.87M) | 218.69M | 902.17M | 1.01B |
| Capital Expenditures | (247.37M) | (375.56M) | (310.32M) | (371.37M) | (254.54M) |
| Acquisitions (Net) | (519.13M) | (1.44B) | (29.47M) | (285.87M) | (99.9M) |
| Purchases of Investments | 0 | (164.66M) | (93.31M) | (43.85M) | (54.75M) |
| Sales of Investments | 0 | 0 | 15.14M | 0 | 4.8M |
| Other Investing Activities | (87.65M) | 3.28M | (62.64M) | 1.45B | 0 |
| Investing Cash Flow | (854.15M) | (1.98B) | (394.72M) | 886.67M | (556.15M) |
| Debt Repayment | 2.75B | (104.29M) | (116.39M) | (111.49M) | (119M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (125.7M) | (3.46M) | 0 | 0 | (123.91M) |
| Dividends Paid | (252.44M) | (592K) | 0 | (962K) | (122.95M) |
| Other Financing Activities | (70.56M) | (65.16M) | 287.89M | (1.25B) | (142.26M) |
| Financing Cash Flow | 2.3B | (173.49M) | 171.49M | (1.36B) | (508.12M) |
| Effect of Forex Changes | 55.46M | 35.55M | (15.09M) | 20.08M | 19.75M |
| Net Change in Cash | 2.1B | (2.13B) | (19.63M) | 450.2M | (38.85M) |
| Free Cash Flow | 349.6M | (386.43M) | (91.63M) | 530.8M | 751.14M |
Grifols, S.A.
NASDAQ:GRFS
Intrinsic Alpha fair value
Locked
Current Price
$8.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.